Song HC

Chinese Center For Disease Control and Prevention

OpenAlex Profile
2
Publications
3
h-index
(91 citations, 12 total works)

Research Topics

Heavy Metal Exposure and Toxicity (4)Radiopharmaceutical Chemistry and Applications (2)Lung Cancer Research Studies (2)Human Health and Disease (2)Stress Responses and Cortisol (1)

Alpha-gal Syndrome Publications

[Mediation effect of inflammatory biomarkers on the association between blood lead levels and blood pressure changes in Chinese adults].

Qu YL, Zhao F, Ji SS, Hu XJ, Li Z, et al.
Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] •

To investigate the role of inflammatory biomarkers in the relationship between blood lead levels and blood pressure changes. A total of 9 910 people aged 18-79 years who participated in the China National Human Biomonitoring in 2017-2018 were included in this study. A self-made questionnaire was used to collect demographic characteristics, lifestyle and other information, and the data including height, weight and blood pressure were determined through physical examination. Blood and urinary samples were collected for the detection of blood lead and cadmium levels, urinary arsenic levels, white blood cells, neutrophils, lymphocytes, and hypersensitive C-reactive protein (hs-CRP). Weighted linear regression models were used to evaluate the associations between blood lead, inflammatory biomarkers and blood pressure. Mediation analysis was performed to investigate the role of inflammation in the relationship between blood lead levels and blood pressure changes. The median (, ) age of all participants was 45.4 (33.8, 58.4)years, including 4 984 males accounting for 50.3%. Multivariate logistic regression model analysis showed that after adjusting for age, gender, residence area, BMI, education level, smoking and drinking status, family history of hypertension, consumption frequency of rice, vegetables, and red meat, fasting blood glucose, total cholesterol, triglycerides, blood cadmium and urinary arsenic levels, there was a positive association between blood lead levels, inflammatory biomarkers and blood pressure (<0.05). Each 2.71 μg/L (log-transformed) increase of the lead was associated with a 2.05 (95%: 0.58, 3.53) mmHg elevation in systolic blood pressure (SBP), 2.24 (95%: 1.34, 3.14) mmHg elevation in diastolic blood pressure (DBP), 0.25 (95%: 0.05, 0.46) mg/L elevation in hs-CRP, 0.16 (95%: 0.03, 0.29)×10/L elevation in white blood cells, and 0.11 (95%: 0.02, 0.21)×10/L elevation in lymphocytes, respectively. Mediation analysis showed that the levels of hs-CRP significantly mediated the association of blood lead with SBP, with a proportion about 3.88% (95%: 0.45%, 7.32%). The analysis also found that the levels of hs-CRP and neutrophils significantly mediated the association of blood lead with SBP, with a proportion about 4.10% (95%: 1.11%, 7.10%) and 2.42% (95%: 0.07%, 4.76%), respectively. This study suggests that inflammatory biomarkers could significantly mediate the association of blood lead levels and blood pressure changes.

View on PubMed →DOI →

A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer.

Kim S, Kim BJ, Kim I, Kim JH, Kim HK, et al.
Journal of Cancer •

GV1001 is a human telomerase peptide vaccine that induces a CD4/CD8 T-cell response against cancer cells, thereby affording an immunological anti-tumor effect. Here, we evaluated the efficacy and safety of GV1001 in combination with chemotherapy in patients with metastatic colorectal cancer who had failed first-line chemotherapy. This multicenter, non-randomized, single-arm phase II study recruited recurrent or metastatic colorectal cancer patients with measurable disease who had failed first-line chemotherapy. Patients received GV1001 and chemotherapy concomitantly based on a pre-established schedule. Cytotoxic chemotherapy and targeted agents (bevacizumab, cetuximab, or aflibercept) were allowed to be used at the discretion of the investigator. The primary endpoint was the disease control rate; secondary endpoints were the objective response rate, progression-free survival, overall survival, and safety outcomes. The baseline serum eotaxin level (a potential predictive biomarker of GV1001) was analyzed. To determine whether an adequate immune response had been induced, a delayed-type hypersensitivity test and a T-cell proliferation test were performed. From May 13, 2015 to October 13, 2020, 56 patients with recurrent or metastatic colorectal cancer treated in seven hospitals of South Korea were enrolled. The median patient age was 64 years (range, 29-82 years); 67.9% were men. Of all patients, 66.1% had left-side colorectal cancer and the RAS mutation was present in 25%. The disease control rate and the objective response rates were 90.9% (95% confidence interval [CI]: 82.4-99.4%) and 34.1% (95% CI, 20.1-48.1%), respectively. The median progression-free survival was 7.1 months (95% CI, 5.2-9.1 months) and the median overall survival was 12.8 months (95% CI, 9.9-15.8 months). The most common all-grade adverse events were neutropenia (48.2%), nausea (26.8%), neuropathy (25.0%), stomatitis (21.4%), and diarrhea (21.4%). Immune response analysis showed that no patient had positive delayed-type hypersensitivity test results; antigen-specific T-cell proliferation was observed in only 28% of patients. The baseline eotaxin level was not associated with any efficacy outcome. Although no clear GV1001-specific immune response was observed, the addition of GV1001 vaccination to chemotherapy was tolerable and associated with modest efficacy outcomes.

View on PubMed →DOI →